For research use only. Not for use in diagnostic procedures.
The AlphaLISA® SureFire® Ultra™ p-STAT1 (Ser727) assay is a sandwich immunoassay for quantitative detection of phospho-STAT1 (phosphorylated on Ser727) in cellular lysates using Alpha Technology.
This kit contains reagents to run 100 wells in 96-well format, using a 60 µL reaction volume.
In the AlphaLISA® SureFire® Ultra™ assay, Donor beads are coated with streptavidin to capture one of the antibodies, which is biotinylated. Acceptor beads are coated with a proprietary CaptSure™ agent that immobilizes the other antibody, labeled with a CaptSure™ tag. In the presence of phosphorylated protein, the two antibodies bring the Donor and Acceptor beads close together, generating signal. The amount of light emission is directly proportional to the amount of phosphoprotein present in the sample.
AlphaLISA® SureFire® Ultra™ kits are compatible with:
Alpha SureFire® kits can be used for:
| Assay Pathway | JAK/STAT |
|---|---|
| Assay Target | STAT1 |
| Assay Target Class | Phosphoprotein |
| Automation Compatible | Yes |
| Detection Method | Alpha |
| Experimental Type | In vitro |
| Shipping Condition | Blue Ice |
| Unit Size | 10,000 Assay Points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
Too many candidates, too little time. The lack of robust, rapid, high-throughput assays to identify and qualify potential therapeutic targets in areas such as cancer research continues to cost valuable time. What if you could increase assay throughput without compromising sensitivity, obtain more data points from each sample and eliminate tedious wash steps? Find out how AlphaLISA® assay technology, combined with the EnVision® multimode plate reader, provides a fast, powerful, homogeneous platform for screening potential inhibitors of PD-L1 (a protein associated with breast cancer tumor cells) expression in human cells.
